Review article: Micrometastasis in colorectal carcinoma: A review
Review article: Micrometastasis in colorectal carcinoma: A review
复制标题
综述文章：结直肠癌微转移：综述
DOI：
--
复制
发表时间：
1998
期刊：
影响因子：
--
通讯作者：
Y. W. Yesus
中科院分区：
文献类型：
--
作者：
R. Calaluce;B. Miedema;Y. W. Yesus
淋巴结转移是结直肠癌术后最重要的预后预测指标。“微转移”这一术语已经从一种形态上的定义演变成了一种用于分子技术的定义。我们回顾文献，以评估通过形态或分子技术检测结直肠癌微转移的重要性，并解决在两者中遇到的技术困难。不建议常规使用免疫组织化学，因为大多数研究表明，在分期或预后方面几乎没有变化。放射免疫引导手术可能被证明是有益的，但良性疾病的假阳性问题需要解决。免疫组织化学检测骨髓抽吸物中的微转移沉积具有最大的临床应用前景。分子技术比免疫组织化学更敏感，但预后价值尚需确定。分子诊断学还可以确定基因改变和突变，这应该会提高我们对转移性结肠癌的理解和分期的准确性。J·奥科尔外科医生。1998年；67：194-202。©1998 Wiley-Liss，Inc.
Lymph node metastasis is the most important predictor of prognosis, after surgery, in colorectal carcinoma. The term “micrometastasis” has evolved from a morphological definition to one that is used with molecular‐based techniques. We review the literature to evaluate the significance of detecting micrometastases in colorectal carcinoma, either by morphological or molecular techniques, and address technical difficulties encountered with both. Routine use of immunohistochemistry is not recommended as most studies show little change in staging or prognosis. Radioimmunoguided surgery may prove beneficial, but problems of false positives in benign diseases need to be addressed. Immunohistochemical detection of micrometastatic deposits in bone marrow aspirates holds the most promise for clinical practice. Molecular techniques are more sensitive than immunohistochemistry, but prognostic value needs to be determined. Molecular diagnostics can also determine genetic alterations and mutations that should improve our understanding of metastatic colon cancer and staging accuracy. J. Surg. Oncol. 1998;67:194–202. © 1998 Wiley‐Liss, Inc.